[ad_1]
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) – Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for ANI Pharmaceuticals in a research note issued on Thursday, July 10th. HC Wainwright analyst B. Folkes forecasts that the specialty pharmaceutical company will earn $1.02 per share for the quarter. HC Wainwright has a “Buy” rating and a $84.00 price target on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.40 EPS, FY2025 earnings at $4.94 EPS and FY2026 earnings at $5.64 EPS.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the business posted $0.82 earnings per share. The business’s revenue for the quarter was up 43.4% compared to the same quarter last year.
A number of other equities research analysts have also recently commented on the company. Guggenheim reissued a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Wall Street Zen downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Finally, Truist Financial lifted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, April 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.88.
Get Our Latest Stock Analysis on ANIP
ANI Pharmaceuticals Price Performance
Shares of NASDAQ ANIP opened at $64.96 on Monday. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $77.00. The stock has a market capitalization of $1.41 billion, a PE ratio of -51.15 and a beta of 0.57. The business has a fifty day moving average price of $63.31 and a two-hundred day moving average price of $62.37.
Hedge Funds Weigh In On ANI Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter valued at about $28,000. US Bancorp DE boosted its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after buying an additional 531 shares during the period. National Bank of Canada FI acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $79,000. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 881 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $166,000. Institutional investors and hedge funds own 76.05% of the company’s stock.
Insider Buying and Selling
In related news, SVP Ori Gutwerg sold 881 shares of the firm’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president owned 89,897 shares in the company, valued at $5,400,112.79. This trade represents a 0.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher Mutz sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider owned 107,317 shares in the company, valued at $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,281 shares of company stock worth $319,270. Insiders own 12.70% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Recommended Stories
Receive News & Ratings for ANI Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ANI Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link